News | Heart Valve Technology | September 19, 2016

Valtech Cardio Presents Data on Tricuspid, Mitral Devices at PCR London Valves 2016

Initial clinical experience of several Cardioband Tricuspid implantations and two-year follow-up results of mitral patients to be presented

Valtech Cardio, Cardioband Tricuspid, Cardioband Mitral, PCR London Valves 2016, study data

September 19, 2016 — Valtech Cardio Ltd. announced that it will present the first-in-man data for its Cardioband Tricuspid (TR) system at PCR London Valves 2016, Sept. 18-20. In addition, updated two-year follow-up results of the multi-center Cardioband Mitral study will be presented at the meeting.

“I am pleased to share my first experience with Cardioband Tricuspid, which shows that it is feasible to perform a successful trans-venous surgical like annuloplasty procedure for the treatment of TR.” said Francesco Maisano, M.D, chairman and professor of cardiovascular surgery at The University Hospital of Zurich who successfully performed the first implantation of Cardioband Tricuspid. “The device has the potential to reproduce surgical standards, although our experience is still limited at the moment.”

A Valtech symposium titled, “Cardioband: Clinical Reality for Mitral and Tricuspid Valve Repair,” will be led by Eberhard Grube, M.D., Ph.D., (University of Bonn, Germany) and Karl-Heinz Kuck, M.D. (Asklepios Klinic St. Georg, Hamburg, Germany) Tuesday, Sept. 20. Panelists will discuss how they are successfully using Cardioband to apply the surgical gold standard in a transfemoral approach.

An accepted talk, “Direct annuloplasty - Cardioband in tricuspid regurgitation,” was presented by Prof. K.H. Kuck (Asklepios Klinic St. Georg, Hamburg, Germany) as part of the “innovation in percutaneous tricuspid valve intervention” session Sunday, Sept. 18.

An accepted abstract, "One Year Follow-up Results of Mitral Valve Transcatheter Annuloplasty System for Mitral Reconstruction Multicentre Trial,” will be presented by Prof. R. S. von Bardeleben (University of medicine Mainz Germany) as part of the "Mitral and Tricuspid Valve Interventions" session held Monday, Sept. 19.

An additional accepted abstract, "Cardioband implantation to treat recurrent mitral regurgitation after MitraClip therapy,” will be presented by Dr. M. Taramasso (University Hospital of Zurich) as part of the "Percutaneous mitral therapies" session Tuesday, Sept. 20.

For more information: www.valtechcardio.com


Related Content

News | Heart Valve Technology

April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop ...

Home April 17, 2024
Home
News | Heart Valve Technology

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

Home April 01, 2024
Home
News | Heart Valve Technology

January 4, 2024 — Findings from a published case series research letter by the Henry Ford Health Structural Heart ...

Home January 04, 2024
Home
News | Heart Valve Technology

December 22, 2023 — TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of ...

Home December 22, 2023
Home
News | Heart Valve Technology

December 18, 2023 — Death rates related to infective endocarditis declined in most adults across the U.S. within the ...

Home December 18, 2023
Home
News | Heart Valve Technology

December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement ...

Home December 12, 2023
Home
News | Heart Valve Technology

November 20, 2023 — Abbott announced new late-breaking data that show advanced heart failure patients living with its ...

Home November 20, 2023
Home
News | Heart Valve Technology

October 24, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announced that novel data from seven research studies ...

Home October 24, 2023
Home
News | Heart Valve Technology

October 17, 2023 — The Patel Children's Heart Institute at St. Joseph's Children's Hospital achieved a milestone ...

Home October 17, 2023
Home
Subscribe Now